A double blind trial of bromocryptine in the treatment of idiopathic bladder instability.
Fifty-one patients (aged 20 to 68 years) entered a 6-week double-blind trial of Bromocryptine, a dopamine agonist. All patients complained of the complex: frequency, nocturia, urgency and urge incontinence which was due to demonstrable bladder instability. No significant improvement in either symptoms or cystometric findings was seen in the Bromocryptine treated as compared with the control group. A high incidence of nausea was noted in the treated groups. The results of this study suggest that Bromocryptine does not have a therapeutic role in the treatment of idiopathic bladder instability.
D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000473:pathology; D014555:Urination Disorders / Q000188:drug therapy / Q000473:pathology
D001971:Bromocriptine